In the last year, several cancers have been the subject of debate regarding whether the label of “cancer” should be applied to them. In 2024, low-risk prostate cancer entered the spotlight as a ...
Bayer (OTCPK:BAYZF) on Wednesday announced plans to seek an expanded label for its prostate cancer therapy Nubeqa (darolutamide) after the oral androgen receptor inhibitor (ARi) as part of combination ...
GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...
An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...
Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. | Cardiovascular (CV) disease is ...
Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis. This is an ASCO ...
-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback